Bilowgii ma jirin qaab gaar ah oo looga hortagi karo saameynta anticoagulant ee dabigatran haddii ay dhacdo dhacdo dhiig bax weyn, si ka duwan warfarin.
Dabcan, nooc ka sii adag xukunka ayaa ah "Markii hore ma jirin hab gaar ah oo looga hortagi karo saameynta anticoagulant ee dabigatran haddii ay dhacdo dhacdo dhiig-bax weyn, si ka duwan warfarin, laakiin daawo dabigatran ah (idarucizumab) waxaa ansixiyay FDA sanadkii 2015".